Table 2 Results of GSEA.

From: Investigation of risk factors for metachronous recurrence in patients with early gastric adenocarcinoma by miRNA–mRNA integral profiling

		All	LA	GA	LB	GB
Enriched in N-group
Myogenesis	ES	0.4	–	0.41	–	0.41
Myogenesis	NOM p-val	0.003	–	< 0.001	–	< 0.001
Hedgehog signaling	ES	0.51	0.57	0.57	–	–
Hedgehog signaling	NOM p-val	0.011	< 0.001	0.003	–	–
Epithelial mesenchymal transition	ES	–	0.3	–	0.37	–
Epithelial mesenchymal transition	NOM p-val	–	0.03	–	0.017	–
Myc targets v2	ES	–	0.64	–	–	–
Myc targets v2	NOM p-val	–	< 0.001	–	–	–
Enriched in MR-group
Interferon alpha response	ES	− 0.72	− 0.69	− 0.67	− 0.66	− 0.68
Interferon alpha response	NOM p-val	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
Interferon gamma response	ES	− 0.6	− 0.59	− 0.54	− 0.51	− 0.61
Interferon gamma response	NOM p-val	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
Xenobiotic metabolism	ES	− 0.5	− 0.48	− 0.46	− 0.4	− 0.49
Xenobiotic metabolism	NOM p-val	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
TNF-α signaling via NF-κB	ES	− 0.48	− 0.4	− 0.45	− 0.44	− 0.45
TNF-α signaling via NF-κB	NOM p-val	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
Complement	ES	− 0.46	− 0.39	− 0.44	− 0.39	− 0.51
Complement	NOM p-val	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
Oxidative phosphorylation	ES	− 0.46	− 0.5	− 0.55	− 0.57	–
Oxidative phosphorylation	NOM p-val	< 0.001	< 0.001	< 0.001	< 0.001	–
IL6 JAK STAT3 signaling	ES	− 0.49	− 0.47	− 0.45	− 0.41	− 0.52
IL6 JAK STAT3 signaling	NOM p-val	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
Allograft rejection	ES	− 0.42	− 0.42	–	− 0.28	− 0.49
Allograft rejection	NOM p-val	< 0.001	< 0.001	–	0.023	< 0.001
Cholesterol homeostasis	ES	− 0.47	–	− 0.48	− 0.49	− 0.41
Cholesterol homeostasis	NOM p-val	< 0.001	–	< 0.001	< 0.001	0.038
Apoptosis	ES	− 0.42	− 0.35	− 0.36	− 0.33	− 0.47
Apoptosis	NOM p-val	< 0.001	0.027	< 0.001	< 0.001	< 0.001
Fatty acid metabolism	ES	− 0.39	− 0.44	− 0.42	− 0.32	–
Fatty acid metabolism	NOM p-val	< 0.001	< 0.001	< 0.001	< 0.001	–
P53 pathway	ES	− 0.37	–	− 0.38	− 0.34	− 0.36
P53 pathway	NOM p-val	< 0.001	–	< 0.001	< 0.001	0.019
Bile acid metabolism	ES	− 0.39	− 0.39	− 0.39	–	− 0.42
Bile acid metabolism	NOM p-val	< 0.001	0.008	< 0.001	–	0.009
UV response up	ES	− 0.37	− 0.36	− 0.35	− 0.39	− 0.39
UV response up	NOM p-val	< 0.001	0.023	< 0.001	< 0.001	0.007
Hypoxia	ES	− 0.36	− 0.35	− 0.34	− 0.33	− 0.35
Hypoxia	NOM p-val	< 0.001	0.019	< 0.001	< 0.001	0.024
Inflammatory response	ES	− 0.34	− 0.35	− 0.32	–	− 0.38
Inflammatory response	NOM p-val	< 0.001	0.017	0.006	–	0.005
Coagulation	ES	− 0.36	− 0.38	− 0.34	− 0.33	− 0.39
Coagulation	NOM p-val	0.003	0.027	0.028	0.015	0.016
Heme metabolism	ES	− 0.34	− 0.38	− 0.36	− 0.35	–
Heme metabolism	NOM p-val	0.009	0.003	< 0.001	< 0.001	–
Adipogenesis	ES	− 0.32	− 0.41	− 0.35	− 0.33	–
Adipogenesis	NOM p-val	0.01	< 0.001	< 0.001	< 0.001	–
KRAS signaling up	ES	− 0.31	–	–	–	− 0.38
KRAS signaling up	NOM p-val	0.015	–	–	–	0.008
Glycolysis	ES	− 0.3	–	–	–	− 0.34
Glycolysis	NOM p-val	0.026	–	–	–	0.025
Mtorc1 signaling	ES	–	–	− 0.3	− 0.27	–
Mtorc1 signaling	NOM p-val	–	–	< 0.001	< 0.001	–
Estrogen response early	ES	–	–	–	− 0.28	− 0.34
Estrogen response early	NOM p-val	–	–	–	0.024	0.037
Reactive oxygen species pathway	ES	− 0.37	–	–	–	–
Reactive oxygen species pathway	NOM p-val	0.079	–	–	–	–
Protein secretion	ES	–	–	− 0.35	–	–
Protein secretion	NOM p-val	–	–	0.009	–	–
KRAS signaling dn	ES	–	− 0.39	–	–	–
KRAS signaling dn	NOM p-val	–	0.007	–	–	–
Pancreas beta cells	ES	–	–	–	–	− 0.54
Pancreas beta cells	NOM p-val	–	–	–	–	0.006
Estrogen response late	ES	–	–	–	–	− 0.39
Estrogen response late	NOM p-val	–	–	–	–	0.003
Spermatogenesis	ES	–	–	–	–	− 0.41
Spermatogenesis	NOM p-val	–	–	–	–	0.02
DNA repair	ES	–	–	–	− 0.28	–
DNA repair	NOM p-val	–	–	–	0.033	–
Peroxisome	ES	–	–	–	− 0.3	–
Peroxisome	NOM p-val	–	–	–	0.038	–
Enriched in N-group at one site and in MR-group at another site
Myc targets v1	N vs MR	–	N	–	–	MR
	ES	–	0.4	–	–	− 0.35
	NOM p-val	–	< 0.001	–	–	0.013
E2f. targets	N vs MR	MR	N	–	–	MR
	ES	− 0.3	0.38	–	–	− 0.52
	NOM p-val	0.033	< 0.001	–	–	< 0.001
G2m checkpoint	N vs MR	MR	N		MR	MR
	ES	− 0.31	0.37	–	− 0.25	− 0.55
	NOM p-val	0.018	< 0.001	–	0.032	< 0.001

GSEA was performed for each site (LA, GA, LB, and GB) and for all sites combined. Thirty-one gene sets enriched in patients with MR and four gene sets dominant in the controls were extracted. Three pathways were considerably enriched in both the controls and patients with MR, depending on the site.
GSEA, Gene set enrichment analysis; LA, lesser curvature of the antrum; GA, greater curvature of the antrum; LB, lesser curvature of the body; GB, greater curvature of the body; MR, metachronous recurrence; ES, enrichment score; NOM-p val, nominal p-value.

Back to article page

Table 2 Results of GSEA.

Search

Quick links